China Biosimulation Market Size & Outlook, 2021-2028
China biosimulation market, 2016-2028 (US$M)
Related Markets
China biosimulation market highlights
- The China biosimulation market generated a revenue of USD 81.7 million in 2021 and is expected to reach USD 269.7 million by 2028.
- The China market is expected to grow at a CAGR of 18.6% from 2022 to 2028.
- In terms of segment, software was the largest revenue generating product in 2021.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
Biosimulation market data book summary
| Market revenue in 2021 | USD 81.7 million |
| Market revenue in 2028 | USD 269.7 million |
| Growth rate | 18.6% (CAGR from 2021 to 2028) |
| Largest segment | Software |
| Fastest growing segment | Services |
| Historical data | 2016 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Software, Services |
| Key market players worldwide | Certara Inc Ordinary Shares, Dassault Systemes SE, Avantium NV, Simulations Plus Inc, Schrodinger Inc Ordinary Shares, Chemical Computing Group, Physiomics, Rosa & Co, Genedata AG, Instem, Yokogawa Electric Corp., Immunetrics |
Other key industry trends
- In terms of revenue, China accounted for 3.4% of the global biosimulation market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In Asia Pacific, Japan biosimulation market is projected to lead the regional market in terms of revenue in 2028.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 215.1 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimulation Market Scope
Biosimulation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China biosimulation market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimulation market will help companies and investors design strategic landscapes.
Software was the largest segment with a revenue share of 67.44% in 2021. Horizon Databook has segmented the China biosimulation market based on software, services covering the revenue growth of each sub-segment from 2016 to 2028.
China held the second largest share of Asia Pacific biosimulation market owing to rising collaborations of industry players with drug manufacturers in this region. Drug manufacturers in China are increasingly focused on leveraging services that facilitate reduction of product recalls and regulatory validation time.
In addition, the Chinese government is heavily investing in developing its computing infrastructure, primarily via the China Grid initiative by Ministry of Education, Chinese Academy of Sciences, and the China National Grid (CNGrid) maintained by the Ministry of Science and Technology. Such favorable initiatives are expected to positively impact the market growth.
Reasons to subscribe to China biosimulation market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China biosimulation market databook
-
Our clientele includes a mix of biosimulation market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China biosimulation market , including forecasts for subscribers. This country databook contains high-level insights into China biosimulation market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
China biosimulation market size, by product, 2016-2028 (US$M)
China Biosimulation Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
